Sun Pharmaceutical Industries
-
{
- All
- News
- Videos
-
India's Pharma Market Expands 10.7% On GLP-1 Launch: Zydus, Glenmark Lead Large-Cap Growth
A majority of companies within Nomura's coverage universe outpaced the broader pharma market in August. Zydus Lifesciences and Glenmark Pharmaceuticals posted the strongest YoY value expansion.
-
Stock Markets Fluctuate In Narrow Range Ahead Of Budget Pesentation
From the 30 Sensex firms, Sun Pharma climbed nearly 3% post announcement of Q3 results, BEL, Power Grid, NTPC and HDFC Bank were among the other major gainers.
-
Lupin, Zydus Lifesciences Among DRChoksey’s Top Picks As Pharma Sector Braces For Q3 — Check Full List
Other notable picks include Alembic Pharma which is expected to benefit from specialty optionality and margin improvement.
-
Laurus Labs, Biocon, Rubicon Lead Motilal Oswal’s Top Picks As Q3 Healthcare Outlook Brightens — Check Details
Q3 Healthcare Results Preview: Motilal Oswal sees strong Q3 for Laurus Labs, Biocon; hospitals to drive sector momentum
-
Sun Pharma Arm Recalls Over 17k Units Of Antifungal Shampoo In US: USFDA
The company is recalling the affected lot due to 'Failed Impurity/Degradation specifications,' the USFDA stated.
-
Adani Enterprises, Airtel, HAL Shine Among Motilal Oswal's Top 10 Wealth Creators In Last Five Years
Adani Enterprises is among the top 10 Fastest Wealth Creators for a record five times in a row.
-
Stocks To Buy: Sun Pharma, Cipla, Rainbow Among Systematix Top Picks In Healthcare Space Post Q2 Results
Systematix’s top picks for the sector include Sun Pharma, Cipla, Ajanta Pharma among others - Check full list.
-
'Buy' Sun Pharma Shares Maintains Nirmal Bang Despite Minor EPS Cuts Due To Near-Term Headwinds
Despite near-term pressures from rising tax rates, operating costs, Nirmal Bang remains bullish on Sun Pharma’s long-term outlook.
-
M&M, Sun Pharma, Indian Hotels, Motherson Wiring, Ramco Cements, Aditya Birla Lifestyle & More Q2 Review
HDFC Securities recommends 'Add' rating for M&M, Motherson Sumi, TeamLease, 'Buy' call for Sun Pharma, Aditya Birla Lifestyle 'Reduce' rating to Indian Hotels, Kaynes, 'Sell' Ramco Cements- here's why
-
Sun Pharma Q2 Review: Systematix Maintains 'Buy' Post Inline Results — Check Target Price
Sun Pharma's India branded generics business recorded sales of Rs 47.3 billion, up 11% YoY and flat QoQ.
-
Q2 Results Updates: Aurobindo Pharma Profit Up, Britannia Bottom Line Jumps; Delhivery Slips Into Loss
Sun Pharma posted a marginal profit rise of 2.6% to Rs 3,118 crore.
-
Pharma Sector Sees Modest Growth Amid US Headwinds; Sun Pharma, Cipla Among ICICI Securities' Top Picks
Pharma Q2 Resulte Preview: ICICI Securities remains cautious on the near-term outlook for pharma sector citing US tariffs uncertainty, NLEM price revision in 2026.
-
US Tariffs: Only Sun Pharma Exposed To Some Headline Risk, But With Limited Earnings Impact
Among Indian companies, only Sun Pharma has sizeable sales from patented drugs in the US, about 17% of 2024-25 revenue.
-
Trump Slaps 100% Pharma Tariffs: What It Means For Indian Companies
Sun Pharmaceutical Industries Ltd. and Biocon Ltd. are key branded players in the US.
-
Sun Pharma Is Well Poised To Sustain Growth In Focus Segments, Says Motilal Oswal Maintaining 'Buy'
Motilal Oswal expects 14% earnings CAGR over FY25-27E, led by 17% sales CAGR in Sun Pharma's specialty segment and 12% in DF/EM markets, and 160bp margin expansion.
-
India's Pharma Market Expands 10.7% On GLP-1 Launch: Zydus, Glenmark Lead Large-Cap Growth
A majority of companies within Nomura's coverage universe outpaced the broader pharma market in August. Zydus Lifesciences and Glenmark Pharmaceuticals posted the strongest YoY value expansion.
-
Stock Markets Fluctuate In Narrow Range Ahead Of Budget Pesentation
From the 30 Sensex firms, Sun Pharma climbed nearly 3% post announcement of Q3 results, BEL, Power Grid, NTPC and HDFC Bank were among the other major gainers.
-
Lupin, Zydus Lifesciences Among DRChoksey’s Top Picks As Pharma Sector Braces For Q3 — Check Full List
Other notable picks include Alembic Pharma which is expected to benefit from specialty optionality and margin improvement.
-
Laurus Labs, Biocon, Rubicon Lead Motilal Oswal’s Top Picks As Q3 Healthcare Outlook Brightens — Check Details
Q3 Healthcare Results Preview: Motilal Oswal sees strong Q3 for Laurus Labs, Biocon; hospitals to drive sector momentum
-
Sun Pharma Arm Recalls Over 17k Units Of Antifungal Shampoo In US: USFDA
The company is recalling the affected lot due to 'Failed Impurity/Degradation specifications,' the USFDA stated.
-
Adani Enterprises, Airtel, HAL Shine Among Motilal Oswal's Top 10 Wealth Creators In Last Five Years
Adani Enterprises is among the top 10 Fastest Wealth Creators for a record five times in a row.
-
Stocks To Buy: Sun Pharma, Cipla, Rainbow Among Systematix Top Picks In Healthcare Space Post Q2 Results
Systematix’s top picks for the sector include Sun Pharma, Cipla, Ajanta Pharma among others - Check full list.
-
'Buy' Sun Pharma Shares Maintains Nirmal Bang Despite Minor EPS Cuts Due To Near-Term Headwinds
Despite near-term pressures from rising tax rates, operating costs, Nirmal Bang remains bullish on Sun Pharma’s long-term outlook.
-
M&M, Sun Pharma, Indian Hotels, Motherson Wiring, Ramco Cements, Aditya Birla Lifestyle & More Q2 Review
HDFC Securities recommends 'Add' rating for M&M, Motherson Sumi, TeamLease, 'Buy' call for Sun Pharma, Aditya Birla Lifestyle 'Reduce' rating to Indian Hotels, Kaynes, 'Sell' Ramco Cements- here's why
-
Sun Pharma Q2 Review: Systematix Maintains 'Buy' Post Inline Results — Check Target Price
Sun Pharma's India branded generics business recorded sales of Rs 47.3 billion, up 11% YoY and flat QoQ.
-
Q2 Results Updates: Aurobindo Pharma Profit Up, Britannia Bottom Line Jumps; Delhivery Slips Into Loss
Sun Pharma posted a marginal profit rise of 2.6% to Rs 3,118 crore.
-
Pharma Sector Sees Modest Growth Amid US Headwinds; Sun Pharma, Cipla Among ICICI Securities' Top Picks
Pharma Q2 Resulte Preview: ICICI Securities remains cautious on the near-term outlook for pharma sector citing US tariffs uncertainty, NLEM price revision in 2026.
-
US Tariffs: Only Sun Pharma Exposed To Some Headline Risk, But With Limited Earnings Impact
Among Indian companies, only Sun Pharma has sizeable sales from patented drugs in the US, about 17% of 2024-25 revenue.
-
Trump Slaps 100% Pharma Tariffs: What It Means For Indian Companies
Sun Pharmaceutical Industries Ltd. and Biocon Ltd. are key branded players in the US.
-
Sun Pharma Is Well Poised To Sustain Growth In Focus Segments, Says Motilal Oswal Maintaining 'Buy'
Motilal Oswal expects 14% earnings CAGR over FY25-27E, led by 17% sales CAGR in Sun Pharma's specialty segment and 12% in DF/EM markets, and 160bp margin expansion.
